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Glucose stimulates insulin secretion in b cells, which sense glucose concentrations through signals derived
from glycolytic metabolism. In this issue of Cell Metabolism, Dor and colleagues (Porat et al., 2011) combine
genetic, transplantation, and pharmacologic approaches to show that glucose also stimulates b cell prolif-
eration through similar metabolic signals, providing a new framework to develop therapeutics for diabetes.Endocrine cells maintain the homeo-
stasis of organisms by secreting specific
hormones in the right amount and at the
right time, a process often regulated by
complex feedback loops. In most endo-
crine feedback systems, the same signal
that stimulates the secretion of a hormone
also stimulates the proliferation of the
hormone-producing cell, thus ensuring
that there are enough cells to maintain an
adequate hormonal production over
extended time frames. In the pancreas,
b cells release insulin to regulate blood
glucose, and glucose concentrations are
amajor feedback signal for insulin release.
It would make sense that increased blood
glucose concentrations also stimulate
b cell growth, although testing this has
not been straightforward. While hypergly-
cemia increases b cell proliferation in
rodents, in vivo and in vitro studies
suggest that hyperglycemia might also
be toxic for b cells (reviewed in Chang-
Chen et al., 2008). In fact, prolonged
hyperglycemia is thought to be delete-
rious for b cells in humans with diabetes
(Chang-Chen et al., 2008; Donath and
Halban, 2004). The direct effects of
glucose on b cell growth, as opposed to
those of other metabolic changes associ-
atedwith uncontrolled diabetes, however,
remain poorly understood.
In the current study, Porat et al. (2011)
tackled this problem with an elegant
combination of genetic, pharmacologic,
and transplantation tools. They used
a transgenic mouse model that enabled
them to ablate 80% of b cells at any
given time. This ablation led to hypergly-
cemia and an increased proliferation of
the remaining b cells, which could be sup-
pressed by transplanting additional b cells
to these mice, suggesting that b cellssomehow sense a reduced demand.
Interestingly, b cells could also sense
changes in workload that did not entail
major changes in glycemia. For example,
if they transplanted b cells in the kidney
of a healthy mouse, endogenous b cells
reduced their proliferation rate, even
though glycemia was seemingly unal-
tered. The findings show that the size of
the b cell pool can be dynamically fine-
tuned to adapt to demands.
How do b cells sense this demand? The
study of Porat et al. (2011) reveals that this
is mediated at least in part by the same
signals that underlie glucose-stimulated
insulin release. Earlier studies established
that in contrast to classic hormones,
which act directly onmembraneor nuclear
receptors, glucose concentrations are
monitored by b cells through signals
generated via its intracellular metabolism
(Malaisse et al., 1979; Matschinsky et al.,
1993; Wollheim and Sharp, 1981). There-
fore, glycolytic flux in b cells parallels
blood glucose concentrations. Specifi-
cally, increased glycemia increases b cell
glycolytic metabolism, which augments
the intracellular ATP/ADP ratio, triggering
closure of the ATP-sensitive potassium
(KATP) channels, causing membrane
depolarization, opening of voltage-sen-
sitive calcium channels, and an increase
in intracellular calcium that stimulates
insulin exocytosis (Ashcroft and Rors-
man, 1989; Wollheim and Sharp, 1981).
Conversely, decreased blood glucose,
and reduced b cell glycolytic metabolism,
shuts off insulin release to prevent severe
hypoglycemia.
In this study, Porat et al. (2011) found
that enhanced b cell glycolytic flux rates
not only initiate insulin release but also
stimulate a compensatory proliferativeCell Metabolismresponse. This was evidenced by their
observation of blocked b cell proliferation
in mice deficient for glucokinase, the
enzyme that catalyzes the first step in b
cell glucose metabolism. Likewise, gluco-
kinase activator compounds induced
b cell proliferation in healthymice. Further-
more, they carried out genetic and phar-
macologic experiments that showed that
closure of b cell KATP channels is required
for glucose-dependent b cell proliferation.
In fact, the signals for glucose-dependent
secretion and proliferation in b cells are so
similar that they beg the question of
whether glucose-dependent insulin
secretion acts in a paracrine manner to
induce b cell growth. Taken together, the
data presented by Porat et al. (2011)
suggest that changes in glycemia—per-
haps even subtle, transient changes—
alter b cell glycolytic flux, which generates
signals that modulate b cell proliferation.
This provides a means to match insulin
production capacity to the organism’s
demands.
What are the potential implications for
human diabetes? The mechanisms re-
ported herein by Porat and colleagues
are likely to be conserved in humans. For
example, recent studies in which human
islets were transplanted in immunodefi-
cient mice show that hyperglycemia
induces human b cell proliferation (Levitt
et al., 2011). Furthermore, human gain-of-
function mutations of the gene encoding
glucokinase result in increasedbcell prolif-
eration (Kassem et al., 2010). Therefore,
perhaps it is time to seriously consider
manipulating glucose signaling to expand
b cell mass. It is currently unclear if long-
term treatmentwith glucokinaseactivators
will necessarily fulfill this goal; in fact, an
oversimplified interpretation of the current13, April 6, 2011 ª2011 Elsevier Inc. 357
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Previewsdata would suggest that KATP channel-
blocking drugs, which have been used for
decades to treat type 2 diabetes, would
stimulatebcell growth inpatients,whereas
the available data suggests that this is not
the case. Clearly, sustained activation of
glucokinase or blocking of KATP channels
differs substantially from the intermittent
stimulus provided by physiologic changes
in glycemia. Furthermore, even if glucose
metabolism is central for b cell growth,
other factors may also be required to
sustain its effects on long-term b-cell
growth. This challenging question is worth
solving, because decreased b cell mass is
central to the pathophysiology of both
type 1 and type 2 diabetes (Donath and
Halban, 2004). Finding a safe compound
that enhances b cell mass is therefore
one of the holy grails of diabetes research.358 Cell Metabolism 13, April 6, 2011 ª2011It is reasonable to assume that unraveling
the sites of interaction of glucose metabo-
lism with mitogenic pathways will provide
more specific targets to develop such
needed therapeutics. The findings re-
ported here by Porat et al. (2011) are thus
likely to spark considerable research in
this area for years to come.REFERENCES
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Cutting down calories prolongs life, but how this works remains largely unknown. A recent study in Nature
(Mair et al., 2011) shows that life span extension triggered by the energy-sensing protein kinase AMPK is
mediated by an evolutionarily conserved transcriptional circuit involving CRTC-1 and CREB.Many of the proteins that control life span
are also involved in nutrient sensing.
One of these nutrient-sensing proteins,
AMP-activated protein kinase (AMPK), is
activated by a wide range of stimuli,
including glucose deprivation, exercise,
and the antidiabetic drug metformin
(Steinberg and Kemp, 2009). AMPK is
necessary for longevity induced by
some, but not all, dietary restriction regi-
mens in C. elegans (Greer et al., 2007;
Greer and Brunet, 2009; Mair et al.,
2009). Interestingly, overexpression of
wild-type or active AMPK is sufficient to
extend life span in worms (Apfeld et al.,
2004; Greer et al., 2007). In mammals,
AMPK has many reported substrates,
including metabolism enzymes (acetyl
CoA carboxylase), signaling molecules
involved in the TOR pathway (RAPTOR,TSC2), autophagy regulators (ULK1),
transcriptional coactivators (CRTC2),
and transcription factors involved in the
insulin pathway (FOXO3) (Egan et al.,
2011; Steinberg and Kemp, 2009). While
there is evidence for a role of the worm
FOXO isoform in AMPK’s ability to extend
life span in C. elegans (Greer et al., 2007),
exactly how AMPK mediates longevity
has not yet been investigated in depth.
In their recent Nature study (Mair et al.,
2011), Mair and colleagues identify
a pathway connecting energy-sensing
molecules to regulatorsofgeneexpression
for life span regulation inC. elegans. Using
an elegant combination of worm genetics,
biochemistry, and immunocytochemistry,
they delineate a conserved transcriptional
network involving the transcriptional coac-
tivator CRTC-1 and the transcription factorCREB in life spanextensiondownstreamof
AMPK (Figure 1). Mair and colleagues
initially show that CRTC-1 knockdown
extendsworm life span, similar to constitu-
tively active AMPK expression or knock-
down of calcineurin, a calcium-activated
phosphatase whose attenuation extends
life span. AMPK directly phosphorylates
worm CRTC-1 at two conserved residues,
thereby excluding CRTC-1 from the
nucleus. A mutant of CRTC-1 that cannot
be phosphorylated at AMPK sites is resis-
tant to life span extension by AMPK and
calcineurin modulations, suggesting that
CRTC-1 phosphorylation is a major medi-
ator of life span extension induced by
AMPK activation and calcineurin
inactivation.
How does CRTC-1 inactivation by
AMPK extend life span? Similar to their
